![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EML3 |
Gene summary for EML3 |
![]() |
Gene information | Species | Human | Gene symbol | EML3 | Gene ID | 256364 |
Gene name | EMAP like 3 | |
Gene Alias | ELP95 | |
Cytomap | 11q12.3 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q32P44 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256364 | EML3 | LZE2T | Human | Esophagus | ESCC | 2.53e-05 | 4.06e-01 | 0.082 |
256364 | EML3 | LZE4T | Human | Esophagus | ESCC | 8.02e-04 | 8.18e-02 | 0.0811 |
256364 | EML3 | LZE20T | Human | Esophagus | ESCC | 2.76e-04 | 1.27e-01 | 0.0662 |
256364 | EML3 | LZE24T | Human | Esophagus | ESCC | 7.03e-12 | 1.59e-01 | 0.0596 |
256364 | EML3 | P1T-E | Human | Esophagus | ESCC | 2.21e-06 | 2.36e-01 | 0.0875 |
256364 | EML3 | P2T-E | Human | Esophagus | ESCC | 8.02e-21 | 2.32e-01 | 0.1177 |
256364 | EML3 | P4T-E | Human | Esophagus | ESCC | 6.74e-09 | 2.92e-01 | 0.1323 |
256364 | EML3 | P5T-E | Human | Esophagus | ESCC | 7.47e-06 | 7.02e-02 | 0.1327 |
256364 | EML3 | P8T-E | Human | Esophagus | ESCC | 2.47e-26 | 4.38e-01 | 0.0889 |
256364 | EML3 | P9T-E | Human | Esophagus | ESCC | 1.70e-13 | 2.12e-01 | 0.1131 |
256364 | EML3 | P10T-E | Human | Esophagus | ESCC | 6.66e-20 | 1.01e-01 | 0.116 |
256364 | EML3 | P11T-E | Human | Esophagus | ESCC | 1.58e-11 | 3.55e-01 | 0.1426 |
256364 | EML3 | P12T-E | Human | Esophagus | ESCC | 9.46e-15 | 1.80e-01 | 0.1122 |
256364 | EML3 | P15T-E | Human | Esophagus | ESCC | 5.43e-06 | 7.47e-02 | 0.1149 |
256364 | EML3 | P16T-E | Human | Esophagus | ESCC | 1.22e-05 | 1.05e-01 | 0.1153 |
256364 | EML3 | P17T-E | Human | Esophagus | ESCC | 1.91e-04 | 2.84e-01 | 0.1278 |
256364 | EML3 | P19T-E | Human | Esophagus | ESCC | 3.29e-06 | 3.45e-01 | 0.1662 |
256364 | EML3 | P20T-E | Human | Esophagus | ESCC | 2.63e-16 | 3.25e-01 | 0.1124 |
256364 | EML3 | P21T-E | Human | Esophagus | ESCC | 2.85e-20 | 4.93e-01 | 0.1617 |
256364 | EML3 | P22T-E | Human | Esophagus | ESCC | 4.08e-02 | 2.52e-02 | 0.1236 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190211513 | Oral cavity | LP | regulation of organelle assembly | 71/4623 | 186/18723 | 2.94e-05 | 4.58e-04 | 71 |
GO:009016913 | Oral cavity | LP | regulation of spindle assembly | 16/4623 | 25/18723 | 3.61e-05 | 5.36e-04 | 16 |
GO:00070591 | Oral cavity | LP | chromosome segregation | 117/4623 | 346/18723 | 7.61e-05 | 9.91e-04 | 117 |
GO:009022412 | Oral cavity | LP | regulation of spindle organization | 21/4623 | 39/18723 | 8.80e-05 | 1.11e-03 | 21 |
GO:000081911 | Oral cavity | LP | sister chromatid segregation | 70/4623 | 202/18723 | 9.20e-04 | 7.82e-03 | 70 |
GO:007050715 | Oral cavity | LP | regulation of microtubule cytoskeleton organization | 53/4623 | 148/18723 | 1.60e-03 | 1.23e-02 | 53 |
GO:009030714 | Oral cavity | LP | mitotic spindle assembly | 27/4623 | 65/18723 | 2.06e-03 | 1.52e-02 | 27 |
GO:005122512 | Oral cavity | LP | spindle assembly | 42/4623 | 117/18723 | 4.39e-03 | 2.80e-02 | 42 |
GO:004828511 | Oral cavity | LP | organelle fission | 145/4623 | 488/18723 | 6.02e-03 | 3.57e-02 | 145 |
GO:00988131 | Oral cavity | LP | nuclear chromosome segregation | 88/4623 | 281/18723 | 6.72e-03 | 3.91e-02 | 88 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EML3 | SNV | Missense_Mutation | c.562G>A | p.Glu188Lys | p.E188K | Q32P44 | protein_coding | tolerated(0.2) | benign(0.019) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
EML3 | SNV | Missense_Mutation | novel | c.2289N>T | p.Lys763Asn | p.K763N | Q32P44 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EML3 | SNV | Missense_Mutation | rs530217979 | c.2086N>C | p.Ala696Pro | p.A696P | Q32P44 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EML3 | insertion | In_Frame_Ins | novel | c.307_308insTTTGGGCTGTAGCCCCAGGAGCTATTT | p.Ser103delinsIleTrpAlaValAlaProGlyAlaIleCys | p.S103delinsIWAVAPGAIC | Q32P44 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
EML3 | insertion | Nonsense_Mutation | novel | c.1768_1769insGATCTACATCTATAGTGTTTCCAGTGATGGTGCCA | p.Ser590Ter | p.S590* | Q32P44 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
EML3 | insertion | Frame_Shift_Ins | novel | c.705_706insACTGGAGACTCAGAGGGGAACATTCTCA | p.Leu236ThrfsTer11 | p.L236Tfs*11 | Q32P44 | protein_coding | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
EML3 | insertion | Frame_Shift_Ins | novel | c.1288_1289insTGGGTTCGAGCAATTCTCCTGCCTCAGCCTCCCGGAG | p.His430LeufsTer97 | p.H430Lfs*97 | Q32P44 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
EML3 | insertion | Nonsense_Mutation | novel | c.969_970insAGAAGGGTAGTTCTGGGTTCATGAGGTGGGAGGTGCTAGTCTTATT | p.Gln324ArgfsTer8 | p.Q324Rfs*8 | Q32P44 | protein_coding | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
EML3 | SNV | Missense_Mutation | novel | c.2453N>A | p.Arg818His | p.R818H | Q32P44 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EML3 | SNV | Missense_Mutation | c.1607N>A | p.Arg536His | p.R536H | Q32P44 | protein_coding | deleterious(0.02) | possibly_damaging(0.637) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |